Vagace JM - Search Results

1

Clinical relevance of erythrocyte ferritin in microcytic anemias.

Vagace JM, Peças A, Groiss J, Bento C, Ribeiro ML, Gervasini G. Vagace JM, et al. Clin Chim Acta. 2015 Mar 10;442:1-5. doi: 10.1016/j.cca.2014.12.035. Epub 2015 Jan 3. Clin Chim Acta. 2015. PMID: 25562818 Free article.

2

Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.

Caravaca F, Vagace JM, Aparicio A, Groiss J, Pizarro JL, Alonso N, Garcia MC, Arrobas M, Cubero J, Esparrago J, et al. Caravaca F, et al. Among authors: vagace jm. Am J Kidney Dis. 1992 Sep;20(3):249-54. doi: 10.1016/s0272-6386(12)80697-4. Am J Kidney Dis. 1992. PMID: 1519605

3

Congenital dyserythropoietic anemia associated to a GATA1 mutation aggravated by pyruvate kinase deficiency.

Pereira J, Bento C, Manco L, Gonzalez A, Vagace J, Ribeiro ML. Pereira J, et al. Ann Hematol. 2016 Sep;95(9):1551-3. doi: 10.1007/s00277-016-2720-0. Epub 2016 Jun 24. Ann Hematol. 2016. PMID: 27342114 No abstract available.

4

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Gervasini G, Vagace JM. Gervasini G, et al. Among authors: vagace jm. Front Genet. 2012 Nov 22;3:249. doi: 10.3389/fgene.2012.00249. eCollection 2012. Front Genet. 2012. PMID: 23189085 Free PMC article.

5

Hyperhaemolysis syndrome responsive to splenectomy in a patient with δβ-thalassaemia: a discussion on underlying mechanisms.

Vagace JM, Casado MS, Bajo R, Gervasini G. Vagace JM, et al. Blood Transfus. 2014 Jan;12(1):127-9. doi: 10.2450/2013.0059-13. Epub 2013 Nov 15. Blood Transfus. 2014. PMID: 24333072 Free PMC article. No abstract available.

6

Ethylenediaminetetraacetic acid-dependent pseudomacrocytosis.

Vagace JM, Rodriguez MÁ, de la Maya MD, Gervasini G. Vagace JM, et al. J Clin Pathol. 2013 Sep;66(9):811-4. doi: 10.1136/jclinpath-2013-201545. Epub 2013 May 30. J Clin Pathol. 2013. PMID: 23723302

7

Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.

Gervasini G, de Murillo SG, Jiménez M, de la Maya MD, Vagace JM. Gervasini G, et al. Among authors: vagace jm. Gene. 2017 Sep 10;628:72-77. doi: 10.1016/j.gene.2017.07.025. Epub 2017 Jul 12. Gene. 2017. PMID: 28710036

8

Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.

Gervasini G, de Murillo SG, Jiménez M, de la Maya MD, Vagace JM. Gervasini G, et al. Among authors: vagace jm. J Pediatr Hematol Oncol. 2017 Nov;39(8):589-595. doi: 10.1097/MPH.0000000000000908. J Pediatr Hematol Oncol. 2017. PMID: 28719513

9

Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma.

Vagace JM, de la Maya MD, Caceres-Marzal C, Gonzalez de Murillo S, Gervasini G. Vagace JM, et al. Crit Rev Oncol Hematol. 2012 Nov;84(2):274-86. doi: 10.1016/j.critrevonc.2012.04.003. Epub 2012 May 11. Crit Rev Oncol Hematol. 2012. PMID: 22578745 Review.

10

Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility to acute lymphoblastic leukemia.

Rodríguez-López R, Donoso M, Fernández-Cavada M, González LM, Margallo A, Corral C, Gallego M, García de Cáceres MT, Herrera T, González C, Vagace JM, Gervasini G. Rodríguez-López R, et al. Among authors: vagace jm. Gene. 2013 Feb 1;514(1):31-5. doi: 10.1016/j.gene.2012.10.090. Epub 2012 Nov 21. Gene. 2013. PMID: 23178241

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters